Veracyte, Inc. (VCYT)
| Market Cap | 3.70B +65.7% |
| Revenue (ttm) | 541.74M +16.9% |
| Net Income | 88.01M +166.3% |
| EPS | 1.08 +160.6% |
| Shares Out | 79.79M |
| PE Ratio | 42.92 |
| Forward PE | 26.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,232,840 |
| Open | 48.09 |
| Previous Close | 47.99 |
| Day's Range | 46.27 - 48.09 |
| 52-Week Range | 22.61 - 50.71 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 47.40 (+2.29%) |
| Earnings Date | May 5, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price target is $47.4, which is an increase of 2.29% from the latest price.
News
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoi...
Veracyte genomic test identifies breast cancer patients who can skip chemo
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice-c...
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 20...
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Grow...
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS
Veracyte (VCYT) announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services’, CMS, Molecular Diagnostics Services Program for patients with muscl...
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
Veracyte price target raised to $42 from $40 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Veracyte (VCYT) to $42 from $40 and keeps a Hold rating on the shares. The firm said the target increase…
Veracyte price target raised to $52 from $48 at UBS
UBS raised the firm’s price target on Veracyte (VCYT) to $52 from $48 and keeps a Buy rating on the shares.
Veracyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth and strong profitability, driven by Decipher and Afirma test expansion. Guidance for 2026 was raised, with new product launches (Prosigna LDT, TrueMRD) expected to fuel future growth. Robust clinical evidence and operational improvements underpin long-term momentum.
Veracyte Earnings release: Q1 2026
Veracyte released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Veracyte Slides: Q1 2026
Veracyte has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Veracyte Quarterly report: Q1 2026
Veracyte has published its Q1 2026 quarterly earnings report on May 5, 2026.
Veracyte Announces First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had...
Veracyte announces new data at AUA 2026 on Decipher portfolio
Veracyte (VCYT) announced that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association, AUA, Annual Meeting, taking place May 15-18 in…
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #AUA26--Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers...
Veracyte Proxy statement: Proxy filing
Veracyte filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Veracyte Proxy statement: Proxy filing
Veracyte filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Veracyte price target lowered to $40 from $43 at Canaccord
Canaccord lowered the firm’s price target on Veracyte (VCYT) to $40 from $43 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results…
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 aft...
Veracyte initiated with a Buy at Jefferies
Jefferies initiated coverage of Veracyte (VCYT) with a Buy rating and $45 price target The firm sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequen...
Veracyte price target lowered to $45 from $50 at Guggenheim
Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $45 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
Veracyte names Kevin Haas as Chief Development and Technology Officer
Veracyt announced that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company’s global product develo...
Veracyte Names Kevin Haas as Chief Development and Technology Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #CancerDiagnostics--Veracyte Names Kevin Haas as Chief Development and Technology Officer.
Veracyte Transcript: Leerink Global Healthcare Conference 2026
Management is focused on high-ROI products, maintaining a 25% EBITDA margin, and launching Prosigna and MRD platforms. Decipher and Afirma drive growth through evidence, share gains, and technology upgrades, while AI and data initiatives support future innovation. Prosigna and MRD launches are expected to build momentum beyond 2026.